ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at Children's National Hospital

Core Insights - ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, has awarded four G-Rex Grants totaling $375,000 to faculty members at Children's National Hospital to support cell and gene therapy initiatives [1][7]. Grant Details - Dr. Patrick Hanley received a $100,000 G-Rex Grant to develop a cost-effective CAR-T cell manufacturing process [2]. - Dr. Michael Keller and Dr. Hanley were awarded a $150,000 G-Rex Grant for optimizing Virus Specific T cell and Tumor Antigen Associate T cell manufacturing processes using G-Rex "M" series bioreactors [3]. - Dr. Amy Hont received a $75,000 G-Rex Grant for developing a closed system G-Rex manufacturing process for ATTACK TAAT cell therapy [4]. - Dr. Conrad Russell Cruz was awarded a $50,000 G-Rex Grant for optimizing CAR-modified TAAT cell manufacturing [4]. Program Impact - ScaleReady's G-Rex Grant Program has surpassed $40 million in no-cost product commitments aimed at advancing cell and gene-modified cell therapy development [7]. - Individual grants can be worth up to $300,000, and recipients gain access to exclusive support from ScaleReady's consortium of partners [7]. New Initiatives - ScaleReady has launched a free program called LEAN Cell & Gene™ in partnership with Hanson Wade to enhance CGT manufacturing efficiency [8]. Industry Context - Children's National Hospital is recognized as a leader in pediatric cell and gene-modified therapies, emphasizing the importance of collaboration in advancing these therapies [5][6]. - The G-Rex manufacturing platform is utilized by over 800 organizations and is involved in approximately 50% of CGT clinical trials [10].